ACTH(4-10) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
It is speculated that these infections exert their effect by critically altering TH1/TH2 regulation. Important elements of newer hygiene hypotheses also include exposure to endotoxins, exposure to pets and growing up on a farm.
After translation, the AGP protein backbones are highly decorated with complex carbohydrates, primarily type II AG polysaccharides. The biosynthesis of the mature AGP involves cleavage of the signal peptide at the N-terminus, hydroxylation on the P residues and subsequent glycosylation and in many cases addition of a GPI-anchor. Glycosylation of the AGP backbone is suggested to initiate in the ERTooltip endoplasmic reticulum with the addition of first Gal by O-galactosyltransferase, which is predominantly located in ER fractions. Chain extension then occurs primarily in the GA. For those AGPs that include a GPI anchor, addition occurs while co-translationally migrating into the ER.
Nishina and Kimura, having tested this technique on 232Th and successfully produced the known 231Th and its long-lived beta decay daughter 231Pa (both occurring in the natural decay chain of 235U), therefore correctly assigned the new 6.75-day half-life activity they observed to the new isotope 237U. They confirmed that this isotope was also a beta emitter and must hence decay to the unknown nuclide 237Np. They attempted to isolate this nuclide by carrying it with its supposed lighter congener rhenium, but no beta or alpha decay was observed from the rhenium-containing fraction: Nishina and Kimura thus correctly speculated that the half-life of 237Np, like that of 231Pa, was very long and hence its activity would be so weak as to be unmeasurable by their equipment, thus concluding the last and closest unsuccessful search for transuranic elements.
Another improvement would be a transplantation of the pancreas or beta cell to avoid periodic insulin administration. This would result in a self-regulating insulin source. Transplantation of an entire pancreas (as an individual organ) is difficult and relatively uncommon. It is often performed in conjunction with liver or kidney transplant, although it can be done by itself. It is also possible to do a transplantation of only the pancreatic beta cells. However, islet transplants had been highly experimental for many years, but some researchers in Alberta, Canada, have developed techniques with a high initial success rate (about 90% in one group). Nearly half of those who got an islet cell transplant were insulin-free one year after the operation; by the end of the second year that number drops to about one in seven. However, researchers at the University of Illinois at Chicago (UIC) have slightly modified the Edmonton Protocol procedure for islet cell transplantation and achieved insulin independence in diabetic people, with fewer but better-functioning pancreatic islet cells. Beta cell transplant may become practical. Additionally, some researchers have explored the possibility of transplanting genetically engineered non-beta cells to secrete insulin.
The report acknowledged that "volunteers or mercenaries" entered Georgia from Russia before the Georgian military operation, adding that "some" non-peacekeeping Russian troops were present in South Ossetia and that Russian air force was already acting against Georgia before the public decision to participate in the conflict was made by the Russian leadership at 14:30 on 8 August.
Sources: en.wikipedia.org
=== Academic Health Center and UC Health (1980s-Present) === The medical school and health colleges had been referred to as the "University of Cincinnati Medical Center" from the early 1980s until 2005. In 2000 a fourth College, the College of Allied Health Sciences joined the University of Cincinnati Medical Center. In 2005, the name was changed from the University of Cincinnati Medical Center to the University of Cincinnati Academic Health Center. In 2010, the Academic Health Center (AHC) became part of the newly formed UC Health organization. UC Health was formed after the dissolution of the Health Alliance of Greater Cincinnati, which had operated the University of Cincinnati Medical Center from 1994 to 2010 and also operated West Chester Hospital starting in 2009. The 2010 dissolution of the alliance left the university with 100% ownership so the alliance was renamed to UC Health and placed under a parent company named UC Healthcare System.
== See also == Alternative abiogenesis scenarios – Proposed alternative scenarios related to abiogenesis Autopoiesis – System capable of producing itself Formamide-based prebiotic chemistry – Scientific hypothesis that life originated from formamide precursors Proto-metabolism – Chemical reactions which turn into modern metabolism GADV-protein world hypothesis – Hypothetical stage of abiogenesis Genetic recombination – Shuffling of genetic material Shadow biosphere – Hypothetical biosphere of Earth Manganese metallic nodules – Mineral concretion found on the sea bottomPages displaying short descriptions of redirect targets Virus world hypothesis – Theory that viruses predate cellular life
Ground substance is an amorphous gel-like substance in the extracellular space of animals that contains all components of the extracellular matrix (ECM) except for fibrous materials such as collagen and elastin. Ground substance is active in the development, movement, and proliferation of tissues, as well as their metabolism. Additionally, cells use it for support, water storage, binding, and a medium for intercellular exchange (especially between blood cells and other types of cells). Ground substance provides lubrication for collagen fibers. The components of the ground substance vary depending on the tissue. Ground substance is primarily composed of water and large organic molecules, such as glycosaminoglycans (GAGs), proteoglycans, and glycoproteins. GAGs are polysaccharides that trap water, giving the ground substance a gel-like texture. Important GAGs found in ground substance include hyaluronic acid, heparan sulfate, dermatan sulfate, and chondroitin sulfate. With the exception of hyaluronic acid, GAGs are bound to proteins called proteoglycans. Glycoproteins are proteins that attach components of the ground substance to one another and to the surfaces of cells. Components of the ground substance are secreted by fibroblasts. Usually it is not visible on slides, because it is lost during staining in the preparation process. Link proteins such as vinculin, spectrin and actomyosin stabilize the proteoglycans and organize elastic fibers in the ECM. Changes in the density of ground substance can allow collagen fibers to form aberrant cross-links.
While fluoxetine remains the only FDA-approved antidepressant for children as young as 8, modern clinical guidelines emphasize rigorous monitoring during the first 12 weeks of treatment—the period identified as having the highest risk for the onset of suicidal ideation.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
The sequence is Met-Glu-His-Phe-Pro-Gly-Pro, a seven-residue peptide. The first four residues correspond to the ACTH(4-10) fragment, and Pro-Gly-Pro is added at the C-terminus. N-acetylated versions also appear in the literature and differ in mass.